SCHEDULE: Rubric Capital Boosts Arcutis Biotherapeutics Stake to 6.75%

Rubric Capital Management LP and David Rosen have disclosed a 6.75% beneficial ownership stake in Arcutis Biotherapeutics, Inc., holding 8,271,577 shares as of December 31, 2025.

Summary

• Rubric Capital Management LP and David Rosen collectively beneficially own 8,271,577 shares of Arcutis Biotherapeutics, Inc. common stock.
• This ownership represents 6.75% of the outstanding common stock of Arcutis Biotherapeutics, Inc.
• The percentage is calculated based on 122,492,192 shares of common stock outstanding as of October 22, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• The Reporting Persons hold these securities in the ordinary course of business and not with the purpose or effect of changing or influencing the control of the issuer.
• Rubric Capital Master Fund LP, an investment fund advised by Rubric Capital, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial stake by an investment firm like Rubric Capital Management suggests confidence in Arcutis Biotherapeutics' long-term prospects, even without an activist intent.

Positives

• A significant institutional investor, Rubric Capital Management LP, has disclosed a 6.75% beneficial ownership stake, which can signal market confidence in Arcutis Biotherapeutics.
• The shares are held in the ordinary course of business, indicating a passive investment strategy rather than an activist intent to influence company control.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Arcutis Biotherapeutics or the reporting persons regarding the company's future performance or strategic direction.

Management Comments

• Michael Nachmani, Chief Operating Officer of Rubric Capital Management LP, and David Rosen, individually, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment by a significant institutional holder. For a biotherapeutics company like Arcutis, a substantial stake by an investment firm like Rubric Capital Management can signal market confidence in its pipeline, commercial prospects, or overall strategy, especially given the capital-intensive nature and inherent risks of the biotech sector. This type of filing is a routine disclosure for investors crossing certain ownership thresholds.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership, not a performance report. Therefore, direct comparisons to industry-specific financial or operational benchmarks are not applicable.
• The accumulation of a 6.75% stake by an investment firm is a notable position within the biotech investment landscape, where institutional backing is often crucial for funding research and development.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.75% stake may instill greater confidence among existing and potential shareholders, potentially stabilizing or positively influencing the stock price.
• Company Management: The presence of a large, passive institutional investor may encourage management to maintain focus on long-term value creation, knowing they have significant shareholder backing.

Key Dates

Recommendation

While the disclosure of a significant passive stake by Rubric Capital Management is a positive signal, indicating institutional confidence, this filing alone does not provide enough fundamental information about Arcutis Biotherapeutics' operational performance, pipeline progress, or financial health to warrant a 'buy' or 'strong buy' recommendation. It primarily reflects an investor's position. A 'hold' recommendation is appropriate, suggesting investors monitor future company developments and Rubric Capital's continued involvement.

Keywords

Arcutis Biotherapeutics, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Biotherapeutics, Investment, Institutional Investor, ARCUTIS